Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.41 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971521 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL12909445 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL942167 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL941276 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL15599050 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL24518229 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL17795749 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL6284997 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL12325135 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| Water SCHEMBL17784184 | 0.98 | PKM (0.43) | PKMFUCA1ARG1FUCA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| EP-2257286-B1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORP PLC (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| EP-2257286-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | Summit Corporation Plc (GB) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009103953-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2009-08-27 | — | — | WO | disclosed |
| EP-0439444-A2 | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors | MONSANTO COMPANY (US) | 1991-07-31 | — | — | EP | disclosed |
| US-5013842-A | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors | MONSANTO COMPANY (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | PKM 456/4885FUCA1 1506/4885ARG1 610/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | PKM 456/4885FUCA1 1506/4885ARG1 610/4885 |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | IRS1, SLC2A1, INSR | PKM 456/4885FUCA1 1506/4885ARG1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.